*Originally published 09/28/22

Medexus Pharmaceuticals (MDP.T), is a Canadian-based specialty pharma firm focused on bringing already approved drugs from different regulatory jurisdictions into the Canadian and American market.

Medexus has a diverse portfolio of revenue-generating products and is currently working on the American FDA approval of treosulfan, a revolutionary new drug used as a conditioning agent in stem cell replacement therapy.

Even though the company is rapidly growing revenue and expects to generate $100 million in the next 12 months, a temporary hiccup with the FDA approval of treosulfan has significantly impacted share price.

Today, Jody sits with CEO and director, Ken d’Entremont, to get an inside look at the company, its portfolio, its progress with treosulfan approval and why investors should be excited about the future and the current market buying opportunity.

Enjoy!